Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1670.57% is 34% above its 5-year average of -2523.84%, near the low end of its 5-year range (-14233.08%–29116.92%).
46.17% above its 12-month average of -3103.56%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-02-28): -7164.01%.
EBITDA MARGIN
-1670.57%
EBITDA MARGIN AVG TTM
-3103.56%
EBITDA MARGIN AVG 3Y
224.85%
EBITDA MARGIN AVG 5Y
-2523.84%
EBITDA MARGIN AVG 10Y
-2615.73%
EBITDA MARGIN AVG 15Y
-2150.11%
EBITDA MARGIN AVG 20Y
-1584.52%
CURRENT VS TTM AVG
+46.17%
CURRENT VS 3Y AVG
-842.99%
CURRENT VS 5Y AVG
+33.81%
CURRENT VS 10Y AVG
+36.13%
CURRENT VS 15Y AVG
+22.30%
CURRENT VS 20Y AVG
-5.43%
Lexaria Bioscience Corp.
Market Cap
$5.35M
EBITDA Margin
-1670.57%
TTM Avg
-3103.56%
3Y Avg
224.85%
5Y Avg
-2523.84%
Market Cap
$5.32M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$5.31M
EBITDA Margin
-5685.74%
TTM Avg
-22429.68%
3Y Avg
-11536.25%
5Y Avg
-7742.59%
Market Cap
$5.24M
EBITDA Margin
-271.50%
TTM Avg
-294.22%
3Y Avg
-453.19%
5Y Avg
-366.18%
Market Cap
$5.22M
EBITDA Margin
-123.71%
TTM Avg
-161.92%
3Y Avg
-255.04%
5Y Avg
-225.97%
Market Cap
$5.21M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $5.35M | -1670.57% | -3103.56% | 224.85% | -2523.84% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Soligenix, Inc. (SNGX)vs › | $5.31M | -5685.74% | -22429.68% | -11536.25% | -7742.59% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -271.50% | -294.22% | -453.19% | -366.18% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -123.71% | -161.92% | -255.04% | -225.97% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -8.85% | 9.13% | 18.32% | 18.32% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -23296.89% | -13717.94% | -7355.60% | -5953.70% |
Gross Margin
100.0%
EBITDA Margin
-1670.6%
Operating Margin
-1683.0%
Net Margin
-3985.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-02-28 | -7164.01% |
| 2025-08-31 | -1532.87% |
| 2025-05-31 | -2137.62% |
| 2025-02-28 | -1579.73% |
| 2024-11-30 | -1444.90% |
| 2024-05-31 | -2056.96% |
| 2024-02-29 | -449.71% |
| 2023-11-30 | -733.99% |
| 2023-08-31 | 29116.92% |
| 2023-05-31 | -3057.45% |
| 2023-02-28 | -6486.37% |
| 2022-11-30 | -1709.41% |
| 2022-08-31 | -1304.39% |
| 2022-05-31 | -2401.24% |
| 2022-02-28 | -4641.14% |
| 2021-11-30 | -14233.08% |
| 2021-08-31 | -4400.72% |
| 2021-05-31 | -1244.09% |
| 2021-02-28 | -560.70% |
| 2020-11-30 | -231.75% |
| 2020-08-31 | -556.21% |
| 2020-05-31 | -3707.54% |
| 2020-02-29 | -2754.74% |
| 2019-11-30 | -8778.75% |
| 2019-08-31 | -796.81% |
| 2019-05-31 | -1950.55% |
| 2019-02-28 | -7447.61% |
| 2018-11-30 | -3107.56% |
| 2018-08-31 | -1272.27% |
| 2018-05-31 | -2437.48% |
| 2018-02-28 | -800.47% |
| 2017-11-30 | -2333.23% |
| 2017-08-31 | -5349.73% |
| 2017-05-31 | -1167.07% |
| 2017-02-28 | -3667.34% |
| 2016-11-30 | -4285.39% |
| 2016-08-31 | -3657.24% |
| 2016-05-31 | -4085.92% |
| 2016-02-29 | -1652.05% |
| 2015-11-30 | -3685.29% |
| 2015-08-31 | -13204.25% |
| 2015-05-31 | -6963.57% |
| 2015-02-28 | -15716.44% |
| 2014-07-31 | -351.56% |
| 2014-04-30 | -222.06% |
| 2014-01-31 | -16.74% |
| 2013-10-31 | -0.50% |
| 2013-07-31 | 23.48% |
| 2013-04-30 | 33.43% |
| 2013-01-31 | 35.40% |
| 2012-10-31 | 60.88% |
| 2012-07-31 | 58.58% |
| 2012-04-30 | -92.01% |
| 2012-01-31 | 0.09% |
| 2011-10-31 | 151.16% |
| 2011-07-31 | -36.67% |
| 2011-04-30 | -5.53% |
| 2011-01-31 | 20.67% |
| 2010-10-31 | -56.83% |
| 2010-07-31 | 59.67% |
| 2010-04-30 | -239.25% |
| 2010-01-31 | -309.60% |
| 2009-10-31 | -97.49% |
| 2009-07-31 | -110.29% |
| 2009-04-30 | -210.27% |
| 2009-01-31 | -26.19% |
| 2008-10-31 | -549.16% |
| 2008-07-31 | 22.61% |
| 2008-04-30 | -0.60% |
| 2008-01-31 | 29.31% |
| 2007-10-31 | 823.83% |
| 2007-07-31 | -1297.59% |
| 2007-01-31 | -628.85% |
